Obeda vs Other GLP-1 Drugs in India: Full Comparison (2026)
How does Obeda compare to Noveltreat, Sematrinity, Ozempic, Wegovy, and Mounjaro in India? This 2026 guide covers price, availability, doses, and which GLP-1 is right for you.
March 2026 transformed India's GLP-1 landscape. Before the semaglutide patent expired, Indian patients had essentially one option: expensive imported Ozempic, if they could afford it. Now there are multiple options at multiple price points.
This guide maps out everything currently available in India and helps you understand the differences that actually matter.
Important: Always consult your healthcare provider before starting any medication. This article is for informational purposes only.
The Current GLP-1 Landscape in India (2026)
| Drug | Molecule | Manufacturer | Type | Est. Monthly Cost | Available? |
|---|---|---|---|---|---|
| Obeda | Semaglutide | Dr. Reddy's (India) | Generic | Rs. 7,560-8,400 (1mg) | Yes |
| Noveltreat | Semaglutide | Sun Pharma (India) | Generic | Rs. 7,000-9,000 (est.) | Yes |
| Sematrinity | Semaglutide | Sun Pharma (India) | Generic | Rs. 4,000-8,000 (est.) | Yes |
| Ozempic | Semaglutide | Novo Nordisk (Denmark) | Branded | Rs. 12,000-18,000 | Limited import |
| Wegovy | Semaglutide | Novo Nordisk (Denmark) | Branded | N/A | Not available |
| Mounjaro | Tirzepatide | Eli Lilly (imported) | Branded | Rs. 18,000-25,000 | Yes (import) |
Obeda vs Noveltreat
Both launched in India on the same day (around March 20-21, 2026). Both contain semaglutide. Both are manufactured by large, reputable Indian pharmaceutical companies.
Key differences:
| Feature | Obeda | Noveltreat |
|---|---|---|
| Manufacturer | Dr. Reddy's Laboratories | Sun Pharma |
| Approved for | Type 2 diabetes + weight management | Chronic weight management only |
| Pen format | Pre-filled pen, 2mg/1.5ml | Pre-filled pen |
| Primary market | Diabetes and obesity | Obesity (weight loss focus) |
Which to choose? Both are good options. If you have type 2 diabetes, Obeda has a broader label covering both indications. If you are focused purely on weight management, either works. Availability at your local pharmacy and your doctor's preference will likely drive the decision in practice.
Obeda vs Sematrinity
Sematrinity is Sun Pharma's diabetes-focused semaglutide brand. It is positioned for type 2 diabetes management, similar to the original Ozempic positioning.
Key differences:
| Feature | Obeda | Sematrinity |
|---|---|---|
| Manufacturer | Dr. Reddy's | Sun Pharma |
| Primary approval | Diabetes + weight management | Type 2 diabetes |
| Weight loss use | Yes (approved) | Off-label for weight loss |
Which to choose? For weight management, Obeda or Noveltreat is the cleaner choice with an on-label approval. Sematrinity is better suited for patients whose primary concern is blood sugar control.
Obeda vs Ozempic
Ozempic is the original branded semaglutide from Novo Nordisk. It remains available in India as a limited import.
Key differences:
| Feature | Obeda | Ozempic |
|---|---|---|
| Molecule | Semaglutide | Semaglutide |
| Manufacturer | Dr. Reddy's, India | Novo Nordisk, Denmark |
| Monthly cost | Rs. 7,560-8,400 | Rs. 12,000-18,000 |
| Pen device | Obeda pen | FlexTouch pen |
| Supply stability | Domestic, stable | Import-dependent |
Which to choose? For new patients, Obeda is the logical choice. For existing Ozempic patients, switching to Obeda is a valid discussion to have with your doctor -- the molecule is identical and the savings are real.
Obeda vs Mounjaro (Tirzepatide)
Mounjaro is a different class of drug. It contains tirzepatide, a dual GIP/GLP-1 receptor agonist. It works on two hormonal pathways (GIP and GLP-1) instead of one.
Key differences:
| Feature | Obeda | Mounjaro |
|---|---|---|
| Molecule | Semaglutide (GLP-1) | Tirzepatide (GIP + GLP-1) |
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 agonist |
| Avg weight loss | 10-15% body weight | 15-22% body weight |
| Monthly cost | Rs. 7,560-8,400 | Rs. 18,000-25,000 |
| Side effects | Nausea, GI effects | Similar GI effects |
Which to choose? Mounjaro has demonstrated higher average weight loss in clinical trials (SURMOUNT trials). However, it is 2-3 times more expensive than Obeda, and long-term data is newer. Obeda is the sensible starting point for most patients. Mounjaro may be considered for patients who do not achieve adequate results on semaglutide.
Which GLP-1 Is Right for You?
There is no single right answer -- it depends on your medical situation. As a general framework:
- Starting semaglutide for the first time: Obeda or Noveltreat -- both accessible, affordable, and well-made
- Type 2 diabetes as primary concern: Obeda or Sematrinity -- discuss with your diabetologist
- Weight loss as primary concern: Obeda or Noveltreat -- on-label approvals for both
- Currently on Ozempic, want to reduce cost: Discuss switching to Obeda with your doctor
- Have not responded well to semaglutide: Ask your doctor about tirzepatide (Mounjaro)
- Budget is very tight: Start at 0.5mg dose with Obeda or Noveltreat -- lowest effective cost entry point
The Obeda side effects guide and results timeline will give you a fuller picture of what to expect on semaglutide before making your decision.
How WeightEasy Works Across All GLP-1 Options
WeightEasy supports patients on any semaglutide product. Whether you are on Obeda, Noveltreat, or Ozempic, the diet, side effect, and coaching support works the same way -- because the molecule is the same.
If you are starting any GLP-1 drug in India, the right support can make a significant difference. WeightEasy helps you stay consistent, manage side effects, and achieve better results.
The Bottom Line
India now has a genuine GLP-1 ecosystem for the first time. For most patients, Obeda and Noveltreat are the most practical starting points -- affordable, domestically manufactured, and well-approved.
The differences between semaglutide brands in India are minimal in terms of clinical outcomes. Price, availability, and your doctor's recommendation should drive the choice.
Consult your healthcare provider before starting any medication.
Sources
- Dr. Reddy's Laboratories -- Obeda product information (March 2026)
- Sun Pharma -- Noveltreat and Sematrinity product information (March 2026)
- Eli Lilly -- Mounjaro (tirzepatide) India pricing (2025-2026)
- SURMOUNT-1 trial: Jastreboff AM et al. -- tirzepatide for obesity (NEJM 2022)
- STEP-1 trial: Wilding JPH et al. -- semaglutide for obesity (NEJM 2021)
- Economic Times Health -- India GLP-1 market overview (March 2026)
- WeightEasy clinical advisory team
FAQ
Which GLP-1 drug is best in India in 2026?
For most Indian patients starting semaglutide, Obeda or Noveltreat are the most practical options -- available at Indian pharmacies, affordable, and manufactured by trusted domestic companies. Mounjaro (tirzepatide) is available but more expensive. The right choice depends on your medical history and your doctor's recommendation.
What is the difference between Obeda and Noveltreat?
Both contain semaglutide and launched in India in March 2026. Obeda is by Dr. Reddy's and approved for both diabetes and weight management. Noveltreat is by Sun Pharma and approved specifically for chronic weight management. Both are good options -- availability and price at your pharmacy may determine the choice.
Is Mounjaro available in India?
Yes, Mounjaro (tirzepatide) is available in India, though at a significantly higher price than Obeda. It contains a different active molecule (dual GIP/GLP-1 agonist) and has shown higher average weight loss in clinical trials, but comes at a higher cost.
Can I switch between GLP-1 drugs?
Yes, but always under your doctor's supervision. Switching between semaglutide brands (Obeda to Noveltreat, for example) is straightforward. Switching between different molecules (semaglutide to tirzepatide) requires a proper transition protocol.
What happens when more GLP-1 generics launch in India?
Competition will increase, prices will fall, and patients will have more options. This is good for accessibility. The core advice remains: choose based on your doctor's recommendation, not advertising.